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Implementation, coverage and 
equity of large-scale door-to-
door delivery of Seasonal Malaria 
Chemoprevention (SMC) to children 
under 10 in Senegal
El-Hadj Bâ1, Catherine Pitt2, Yankhoba Dial3, Sylvain Landry Faye4, Matt Cairns2, Ernest Faye4, 
Mouhamed Ndiaye4, Jules-Francois Gomis4, Babacar Faye4, Jean Louis Ndiaye4, Cheikh Sokhna1, 
Oumar Gaye4, Badara Cissé2,4 & Paul Milligan  2
SMC has been introduced widely in the Sahel since its recommendation by WHO in 2012. This study, 
which provided evidence of feasibility that supported the recommendation, included school-age and 
pre-school children. School-age children were not included in the 2012 recommendation but bear an 
increasing proportion of cases. In 2006, consultations with health-staff were held to choose delivery 
methods. The preferred approach, door-to-door with the first daily-dose supervised by a community-
health-worker (CHW), was piloted and subsequently evaluated on a large-scale in under-5’s in 2008 and 
then in under-10’s 2009–2010. Coverage was higher among school-age children (96%(95%CI 94%,98%) 
received three treatments in 2010) than among under 5’s (90%(86%,94%)). SMC was more equitable 
than LLINs (odds-ratio for increase in coverage for a one-level rise in socioeconomic-ranking (a 5-point 
scale), was 1.1 (0.95,1.2) in 2009, compared with OR 1.3 (1.2,1.5) for sleeping under an LLIN. Effective 
communication was important in achieving high levels of uptake. Continued training and supervision 
were needed to ensure CHWs adhered to treatment guidelines. SMC door-to-door can, if carefully 
supervised, achieve high equitable coverage and high-quality delivery. SMC programmes can be 
adapted to include school-age children, a neglected group that bears a substantial burden of malaria.
Since 2012, countries in the Sahel have started to introduce Seasonal Malaria Chemoprevention (SMC) for chil-
dren under 5 years of age. The current policy is limited to children under the age of 5 but in many parts of the 
Sahel there is a substantial burden of malaria in older children who could benefit from SMC. SMC involves 
monthly antimalarial treatment for up to four months to prevent malaria, and is recommended by the World 
Health Organization (WHO) for children who live in areas with intense and highly seasonal malaria transmis-
sion in the Sahel sub-region1. In 2017, twelve countries had SMC programmes reaching about 15million chil-
dren (Burkina Faso, Cameroon, Chad, Gambia, Ghana, Guinea, Guinea Bissau, Mali, Niger, Nigeria, Senegal 
and Togo). In Senegal, children up to 10 years of age are included, while in all other countries SMC is limited to 
children under 5 years of age in accordance with the current WHO recommendation.
Prior to WHO’s recommendation, key concerns regarding SMC were the feasibility of delivery on a large scale 
through routine health services and the most appropriate delivery methods, especially given the requirement that 
SMC be delivered at monthly intervals during the rainy season. Preliminary findings from the study reported here 
contributed to WHO’s 2012 policy recommendation. The possibility of extending the recommended age range to 
include children up to the age of 10 is now also under consideration.
Several possible delivery methods for SMC were considered for children under 5. In The Gambia, a 
cluster-randomized trial in 12,000 children found that village health workers achieved substantially higher cov-
erage than delivery through mobile, nurse-led vaccination clinics, and that delivery by village health workers was 
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both equitable and more cost-effective2. In Ghana, a small village-randomized trial found that community volun-
teers achieved slightly higher coverage than health workers in clinics and outreach clinics, although both achieved 
high coverage; they concluded that a combination of approaches could be necessary in some settings3. In Mali 
and Burkina Faso, a qualitative study found that parents and community health workers (CHWs) involved in a 
clinical trial of SMC efficacy, largely favoured future SMC distribution from fixed points in villages, the method 
used in the trial, and were concerned about the ability of families to administer the second and third daily doses of 
amodiaquine (AQ) at home4. The studies in Ghana and The Gambia included relatively small numbers of children 
in a single year with substantial implementation support from researchers, while the efficacy trials in Mali and 
Burkina Faso employed researcher-led distribution strategies. Implementation research in an operational setting 
was therefore important to address questions as to whether and how routine health services could successfully 
deliver SMC on a large scale and achieve high and equitable coverage, and about how to reach older children. In 
Senegal, consultations were held with health staff to select the most appropriate method of delivery. This method 
was piloted, and subsequently evaluated on a large scale in a range of settings in children under 5 and then in 
children up to 10 years of age (children aged at least 3 months and who, at first monthly treatment of the year, are 
less than 10 years old. Children who reach 10 years of age during SMC continue to receive treatments to the end 
of the transmission season but are not eligible the following year). In this paper, the findings from the pilot study, 
and the results on SMC delivery from the large-scale study, are presented. The primary results from the large-scale 
study have been published separately5.
Study Overview. We report on the process of developing and adapting the methods for implementing SMC 
in central Senegal over a 5-year scale-up period and the levels of coverage and equity achieved. A randomized 
trial in Niakhar, Senegal6 had shown that monthly administration of antimalarial treatment (a one-day regimen 
of sulfadoxine plus one dose of artesunate) to children resulted in an unprecedented level of protection, with an 
efficacy of 86%. A subsequent trial7 showed that sulfadoxine-pyrimethamine plus amodiaquine (SP + AQ) was 
an even more effective regimen. Use of SP + AQ required a 3-day course of treatment each month, but had the 
advantage, in addition to improved efficacy, that its use for SMC would allow artemisinin combinations to be 
reserved for treatment of acute malaria cases, where their rapid action would be most beneficial. Implementation 
research to determine how SMC with SP + AQ could be delivered most effectively was then an urgent priority. 
In 2006 and 2007, a pilot study was conducted to develop practical methods for implementation suitable for the 
local health system context; SMC was delivered in the catchment areas of two rural and one semi-urban health 
post, while one rural health post was observed as a control in 2006 and began implementation from 2007. Over 
the following three malaria seasons (2008–10), SMC was adapted and rolled out in a stepped wedge randomized 
implementation trial, reaching 9 rural and semi-urban health posts’ catchment areas in 2008, 27 in 2009, and 
more than 150,000 children across 46 health posts in 2010 (Table 1). Of the 78 health posts in the three main 
implementation districts, 9 rural and semi-urban health posts were observed as controls throughout the study 
period and 23 urban health posts were excluded, as operational conditions and epidemiology were expected 
to differ substantially in urban settings. Further details of the design and randomization process are provided 
elsewhere5.
For the pilot study and the first year of large-scale implementation, SMC was delivered to children under 
5 (aged 3 to 59 months), however, in response to the changing malaria epidemiology, the target age range was 
expanded in 2009 and 2010 to children under 10 (aged 3 to 119 months).
Year (phase) Target age group District
Rural or semi-
urban
Health posts 
implementing SMC CHWs
Children1 per 
CHW (mean)
Children1 per CHW 
per day (mean)
2006 (pilot) 2–59 months Cherif Lo Health Post Rural 1 35 65 22
Medine Health Post Semi-urban 1 21 70 23
Pambal Health Post Rural 1 20 96 32
Total 3 76 74 25
2008 (main study) 3–59 months Bambey District Rural 3 50 87 29
Fatick District Rural 3 68 73 24
Mbour District Semi-urban 3 77 81 27
Total 9 195 80 27
2009 (main study) 3–119 months Bambey District Rural 9 254 155 39
Fatick District Rural 10 178 166 42
Mbour District Semi-urban 8 153 138 34
Total 27 585 154 39
2010 (main study) 3–119 months Bambey District Rural 16 380 199 51
Fatick and Niakhar 
Districts2 Rural 17 272 181 45
Mbour District Semi-urban 13 238 179 37
Total 46 890 186 44
Table 1. Implementation summary. 1Includes doses that were refused or rejected. 2In 2010, Fatick was officially 
divided into two districts: Fatick and Niakhar. For comparability, they are listed together for all three years.
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In the following sections, we describe the setting and then report on the pilot study, followed by the main 
implementation trial, with the aim of informing ongoing implementation across the Sahel and further policy 
development. The study profile is shown in Fig. 1.
Setting. Tivaouane District (Thiès Region) was selected for the pilot because it included both rural and 
semi-urban health posts and, when the study was planned, suffered high incidence of malaria. The main imple-
mentation trial was conducted in the three neighbouring districts of Mbour (Thiès Region), Bambey (Diourbel 
Region), and Fatick (Fatick Region), which shared similar health and socio-demographic characteristics to 
Tivaouane. In 2010, Niakhar District was created from part of Fatick District and continued to be included in the 
implementation area. The study population is described by Cisse et al.5.
In 2010, the 46 health posts delivering SMC in the main study area served a median population (all ages) 
of 10,236 people (range: 1,943 to 45,261) per health post. Each health post is normally staffed by a full-time 
head nurse and three support staff, all considered CHWs: a community health agent (agent de santé communau-
taire, ASC) acting as an assistant nurse, a CHW (relais) responsible for taking payments, and a birth attendant 
(matrone); in some posts, a midwife is also employed.
In Senegal, several categories of CHW are involved in primary health care programmes. Community health 
agents or agents de santé communautaire (ASC) are literate, lay health workers who have received specific training 
and perform auxiliary roles, including basic curative care, within the health post or health hut. By contrast, relais 
are more numerous and expected to be a key link between the health post and local communities; their qualifica-
tions vary and the head nurse calls on them to support the health post in information, education, and communi-
cation and in mass distribution campaigns, which the ASCs also support. Relais polyvalents mainly support the 
expanded programme on immunization, but also contribute to HIV/AIDS, malaria, tuberculosis, nutrition, and 
water and sanitation activities. Both the ASCs and relais polyvalents in the study area are members of associations, 
which perform functions similar to labour unions. Certain other relais work on a single programme, notably 
nutrition. ASC’s are paid a monthly salary by the Comité de Santé, a local committee that oversees the work of the 
health post and decides how resources are used. Relais are paid on a daily basis through the district health office.
For large campaigns, including SMC, additional literate community members, such as secondary school stu-
dents, may also be called on to act as relais on a temporary basis. Twice per year (usually June and December) 
CHWs deliver Vitamin A and mebendazole to children under 5 year through door-to-door visits. In Bambey dis-
trict, from 2006 to 2009, CHWs also delivered azithromycin to treat trachoma to all residents aged over 6 months 
except pregnant women each year in November - December. We use the umbrella term “CHW” throughout the 
paper to refer to both the small number of ASCs, the much larger number of relais, and additional community 
members acting as temporary relais.
Pilot Study
Pilot methods. Developing the approach to delivery. Consultation process: The delivery approach was 
developed through a district-level consultation process. The district medical officer (YD) chaired group discus-
sions with the district public health officer, district health communications officer, the head nurses of the four 
health posts involved in the pilot, leaders of two CHW unions, staff of the Service de Lutte Anti-Parasitaire 
(SLAP), and members of the research team (including PM, BC, EF, SF). The research team presented the interven-
tion approach, which called for children to receive a therapeutic course of SP + AQ each month for three months 
of the malaria transmission season (September-November). The need to ensure strict timing, accurate dosing, 
good adherence, and safe drug use were highlighted.
Figure 1. Study profile.
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Delivery of SMC door-to-door, at fixed points in each village, and at health facilities, were considered. 
Supervised administration of all three daily doses, or of the first dose only, each month, and the possibility of 
leaving treatment drugs to be administered unsupervised, were also examined. How best to document SMC doses 
- on the existing health card or on an SMC record card – was also debated. Likely implementation challenges 
and options were discussed, and experiences shared of successful door-to-door CHW campaigns for Vitamin 
A, deworming, vaccination, azithromycin for trachoma, and other programmes. The research team intended 
that the three health posts would each implement their chosen approach in the pilot study to identify the most 
successful strategies. The head nurses, however, all agreed that CHWs should deliver SMC door-to-door. Key 
factors in this choice were the positive experiences of door to door delivery of other interventions; concerns, 
based on previous experience, that attendance at fixed points for a preventive intervention would be poor; and 
because it was felt that CHWs needed time to explain the nature and purpose of the intervention to each family to 
ensure acceptability and adherence and to avoid misconceptions and spread of rumours about drug side effects. 
CHWs delivering these messages should be individuals known and trusted in the community. It was felt that if 
this approach was adopted, the tablets for days 2 and 3 could be left with the caregiver who could be relied upon 
to ensure that the course of treatment was completed without the need for supervision. A door-to-door strategy 
was therefore adopted by all three health posts. It was agreed that effective community sensitisation would be 
needed to explain the programme and to publicise dates of campaigns. It was considered important that families 
would have a record of the treatments their children received, so an SMC card was devised. The importance of 
using rapid tests to diagnose malaria in children attending clinic with fever (as opposed to treating presumptively 
as if malaria) was also noted, since in children who had received SMC, fever was less likely to be due to malaria.
Eligibility, Drug dosage and formulation, and administration: For the pilot studies, all children aged 2 
to 59 months who were normally resident in the study area were considered eligible unless they had a fever (in 
which case they should be referred to the nearest health structure where cases of fever were tested for malaria), or 
had a history of allergy to SP or AQ. Dosage of AQ and SP should, ideally, be based on a child’s weight, however, 
this is often impractical and especially in door-to-door campaigns. Anthropometric survey data (K Simondon, 
unpublished data 2004) were therefore analysed to generate locally appropriate age-based dosage guidelines cho-
sen to minimize under- and over-dosing while keeping simple age categories, and avoiding the use of quarter 
tablets. Breakable, non-dispersible tablets of AQ (200 mg) and SP (500 mg sulphadoxine/25 mg pyrimethamine) 
were used. The analysis indicated that children aged 2 to 11 months should receive half tablets of SP and AQ on 
the first day, followed by half tablets of AQ on the two subsequent days, and that from age 1 to 4 years, children 
should receive whole tablets. These findings conflicted, however, with the nurses’ experience, as when this drug 
combination was Senegal’s interim first-line treatment, the national guidelines indicated that whole tablets should 
only be given from the age of two years. Given local health workers’ concerns about side effects of SP and despite 
researchers’ concerns about under-dosing, agreement was reached that whole tablets would only be given from 
2 years, and that care would be taken to ensure that only children under 5 would be included in the campaign, as 
older children, if treated with the dose for 1–4-year-olds, could be under-dosed (Table S1).
Supervision of all three daily doses was considered impractical and the health workers highlighted that 
mothers were already experienced in administering curative multi-day drug regimens, including antibiotics and 
antimalarials, at home. The consultative group therefore decided that CHWs should demonstrate for the child’s 
caregiver proper administration of the first day’s tablets, and that the caregiver could administer the two remain-
ing daily doses of AQ unsupervised at home. The breakable, non-dispersible tablets were to be crushed and mixed 
with sugar and water using plastic cups, spoons, and sugar carried by the CHWs and the household’s usual water 
supply.
AQ was known to be associated with an increased risk of vomiting, and because of AQ’s bitter taste, some of 
the children were likely to spit out some of the medicine. Children were re-dosed by the health worker if the first 
dose was vomited while the health worker was present. However, given that it would often not be clear how much 
of the medicine had been ingested, caregivers would be advised not to re-dose, to avoid the possibility of overdos-
ing, and avoiding the complication of providing families with repeat doses.
Training community health workers: Members of the district health management team, the research team, 
and head nurses collaborated to lead separate, one-day trainings for CHWs in each of the three pilot health posts. 
In addition to eligibility criteria, dose, and drug administration, the CHWs were also trained in communication, 
side effects, record keeping, and operational issues.
Communication with local communities: Each health post nurse, in agreement with their health committee, 
organized a meeting with village heads and local leaders to explain the activities and timing of monthly rounds. 
Each village head was asked to circulate information within their village. Additional social mobilisation activities 
were organised in each health post area. In one health post, communities were informed through church services 
and in mosques, and a caravan toured the villages - village criers (griots, criers) hired for 5 days to circulate on 
horse carts in the intervention villages with loudspeakers to deliver (often witty!) slogans regarding the upcoming 
SMC delivery. In the other health posts, local meetings were held in different parts of the health post area by the 
nurse and by CHWs several days before the start of SMC delivery.
During SMC delivery, CHWs explained the strategy, asked for consent, and explained how to administer treat-
ment doses. CHWs were trained to make caregivers aware of symptoms of known side effects and to advise them 
to bring the child to the clinic immediately if she/he was unwell after SMC treatment. CHWs were also trained 
to explain that no malaria interventions are completely effective, that all members of the household should sleep 
under a treated bed net, and that if the child is unwell with a fever, it could be malaria, so health care should be 
sought immediately. CHWs were trained to ask before giving drugs about history of allergies to medicines and 
side effects to previous intake of SMC drugs.
Record keeping: The CHWs distributed SMC cards to all families in September 2006. When these were not 
retained in subsequent years, CHWs began noting receipt of SMC on children’s vaccination cards instead. Tally 
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sheets were used by each CHW pair to record the number of each type of tablet received, used, and returned, 
and numbers of treatments administered by age group. Village registers were used to provide a record of all the 
monthly treatments a child received. Supervision sheets were used to summarise the number of children treated 
by age group, and tablets used and returned, by each CHW team.
Logistics: CHWs themselves highlighted the importance of working in pairs, with one explaining the inter-
vention to the family and administering the drugs, and the other checking the child’s eligibility and completing 
the family’s record card and the administrative tally sheet.
The health posts nurses were responsible for working out each CHW pair’s area of responsibility, route, and 
target number of children to be reached each day, as they were experienced in this type of planning for other 
campaigns.
Each CHW pair took bags of tablets, a bag of sugar, 2 cups, 2 spoons for crushing the tablets, a register, and 
forms for recording drug usage. They were also told to return to the household if a child was declared absent. 
During visits the following month, they were asked to check for adverse events and document vomiting, refusals 
and absence on a register.
The CHWs were paid at daily rates similar to other campaigns, 3500 CFA per day (=US$ 7.5 in 2006), for 3 
days each month over 3 months. This rate, which included transport costs, was proposed by the district medical 
officer and agreed with the CHW union.
Supervision and monitoring: The district public health officer, district medical officer, or the research team’s 
district supervisor visited each health post once per day during SMC administration and PIs (BC, PM) visited 
monthly.
Pilot study data collection and analysis. In addition to the routine monitoring data, a cross-sectional survey was 
conducted at the end of the transmission season to gather data on receipt of SMC, access to health care, use of 
bed nets, socio-economic status, vaccination history, and nutritional status. A total of 686 children living in the 
catchment areas of the 4 health posts were selected for inclusion using a form of probability sampling that did 
not require a sampling frame: 40 clusters representing 32 villages in the pilot area were selected with probability 
proportional to the number of children under 5 estimated in district health records. Rough sketch maps were 
then used to divide the 40 clusters into geographical segments of approximately equal numbers of dwellings, 
from which 40 segments were selected by simple random sampling and all children under five in each of the 40 
segments were included.
To monitor for adverse events and check compliance with the unsupervised AQ doses on days 2 and 3, field-
workers visited a systematic sample of children aged 2 to 59 months (as of September) on day 4 in November (i.e. 
three days after the SMC distribution). The sample was stratified by health post and caregivers of 636 children in 
the 3 implementing health posts and of 216 children in the control post were interviewed. In addition, passive 
surveillance in health facilities was also used to monitor adverse events, which are discussed in greater detail 
elsewhere8.
Malaria cases were detected through passive surveillance using rapid diagnostic tests (RDTs) in the partici-
pating health posts.
A series of interviews and focus group discussions were used to explore the acceptability of the intervention to 
health workers and communities. Direct observation was done in homes to observe interactions between health 
workers and caregivers and the administration of supervised and unsupervised SMC doses.
Ethics. The pilot study and main trial were approved by the ethics committee of the London School of Hygiene 
& Tropical Medicine and by the Conseil Nationale de Recherche in Senegal. Before the pilot study, and for the 
main study, meetings were held with local authorities and health staff to explain the aims and activities of the 
research. On the first occasion, when the intervention drugs were delivered through house-to-house visits, verbal 
consent to participate was sought from the mother or carer of each eligible child using a standard script translated 
into the appropriate local language which explained the purpose of the project, the purpose of the drug treat-
ment, the common side effects that might be experienced and that severe side effects, while possible, are unlikely. 
Consent was documented in a register by the community worker. Consent was sought separately for participation 
in surveys after explaining the procedures involved using a standard script. The studies followed good clinical 
practice guidelines.
Pilot study results. In total, children received 5059, 5209, and 5292 courses of SMC in September, October, 
and November 2006, respectively, and 4635 children received all three intended courses of treatment. An esti-
mated 81% (95% confidence interval: 76% to 85%) of eligible children received all 3 scheduled courses of treat-
ment, while 88% received at least one dose (Table 2).
Amongst children in the 72 intervention villages (population < 5yrs approximately 5630), 4 RDT-confirmed 
cases of malaria were detected, as compared with 25 confirmed cases in the control villages (population 1153), 
giving an incidence rate ratio of 0.03 (95%CI 0.015,0.07). Incidence of solicited adverse events recorded on day 4 
after the initial dose of SMC (Fig. 2) was similar amongst children who received SMC and children who did not 
for all symptoms (including vomiting), except for drowsiness, which was more common in children who received 
SMC (risk ratio 2.3, 95% CI 1.2–4.6), and caregiver-reported fever and headache which were both less common 
in children who received SMC (risk ratio for fever: 0.57, 95% CI 0.43 to 0.76, and for headache 0.29, 95% CI 0.12 
to 0.68).
The most common reason for not receiving SMC was being away from the village at the time of delivery. 
Amongst children who missed one or more courses of treatment, 56% of children and/or their mothers were tem-
porarily away from home or not living in the village at the time of delivery; in only 4% of cases did parents refuse 
and in 6.5% of cases the mother reported that the CHW did not visit her house. Of the 513 mothers interviewed 
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on day 4 whose child had received the supervised dose on day 1, 5% said they had not given the day 2 dose of AQ 
and 10% said they had not given the day 3 dose; of these, half said they had forgotten, while 11% attributed the 
omission to the bad taste, 10% to the mother’s absence, 9% to vomiting, and only 2% to the child’s refusal. 80% 
of mothers had retained the blister pack for inspection, of these, 12% had left-over medication. Drawing on the 
qualitative research, the team identified several ways in which implementation could be improved, which are 
discussed in the next section.
During direct observation, supervision of the first dose was generally adhered to, but one instance was 
observed where the relais did not supervise the first dose, leaving the drugs with the caregiver. Some mothers 
with children of different age groups found it difficult correctly to distinguish the dose for each child. Community 
sensitization did not reach some households and the measures employed in some health post areas (where the 
mobile caravan was used) were more effective than those relying solely on local meetings, although the latter were 
important in allowing the opportunity to answer questions from the community. Explaining the nature of the 
common side effects and that these were generally mild and short-lived, was important in promoting adherence 
and to avoid spread of rumours. In general, the intervention was well accepted. Malaria was felt to be the major 
health concern, and parents were particularly concerned for their children’s health and recognized that bednets 
provide only partial protection, and therefore welcomed the use of preventive medicines. Despite the bitter taste 
of AQ, high coverage was achieved with good adherence to both supervised and unsupervised doses.
Initial costing at the pilot stage indicated costs of delivery were likely to be affordable.
Findings were presented at a meeting of the project team at which the Director of Medical Services, the 
regional medical officer, and the research focal point of the national malaria control programme, and repre-
sentative of the funder were present. Key messages from the study were fed back to participants in a community 
meeting. The Director of Medical Services then chaired a working group including heads of the departments of 
community health and of nutrition, district medical officers from the study areas, and members of the research 
team (PM, BC), which considered delivery approaches for a potential national scale-up, and whether SMC could 
be delivered alongside other interventions such as Vitamin A and deworming.
From 2007 to 2009, SMC was delivered in all 4 health posts in the pilot area, in 2010 SMC was discontinued in 
these health posts and implementation started in four other health posts in the same district with a higher burden 
of malaria.
The intervention had been known as Intermittent Preventive Treatment in children (IPTc), or Traitement 
Préventif Intermittent (TPI) chez les enfants. From 2008, in Senegal it was referred to as PSP (Prévention 
Saisonniare du Paludisme) to avoid any confusion with IPT in infants which the country had decided not to adopt.
Large-Scale Implementation
Large-scale implementation methods. The design of the stepped wedge trial is described in Cisse et al.5 
and NDiaye et al.8. Briefly, 54 health posts were randomized with respect to the timing of when SMC would be 
introduced, 9 to start in 2008, 18 to start in 2009, 18 in 2010. The remaining 9 did not implement SMC.
Coverage (95% CI)
Health post
Cherif Lo Medine Pambal Total
Sep 86% 72% 91% 85% (80–90%)
Oct 91% 74% 93% 89% (84–93%)
Nov 89% 75% 92% 87% (84–91%)
All 3 monthly courses 81% 67% 86% 81% (76–85%)
Table 2. Pilot study: coverage in Tivaouane District, 2006.
Figure 2. (A) Percentage of children in whom caregivers reported symptoms, 4 days after SMC distribution, in 
children who received SMC and in children in control areas who did not receive SMC, (B) Risk ratio for each 
reported symptom (SMC:No SMC);ratios above 1 indicate increased risk in children who received SMC).
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Large-scale delivery. Implementation methods built on the pilot study with the modifications described below. 
These adaptations addressed findings from the pilot study, changes in epidemiology, difficulties as they arose, and 
the challenges of gradually scaling up delivery while scaling back research team support over three years, so that 
in 2010, district health management teams could deliver SMC largely independently in 46 health posts. Early in 
2010, members of the research team attended a meeting with the Global Malaria Programme of WHO, at which 
available evidence on IPTc was discussed preparatory to convening a review by the WHO Technical Expert Group 
on chemoprevention. A key point was the need to ensure that use of antimalarial drugs for preventive treatment 
did not undermine the policy that use of antimalarial drugs for case management should be based on a positive 
parasitological diagnosis (rather than presuming fever indicated malaria). For this reason, in the 2010 imple-
mentation, there was added emphasis on the need to check if the child had a fever, and refer all febrile children 
so that they could be tested for malaria at the health facility and then treated with ACT if positive, or given SMC 
treatment if they were negative.
Communication: A series of meetings were held with the local government authorities and district health 
staff to explain the aims and activities of the project. In each of the three districts of the project area, the préfet 
(the senior local government administrative officer of the département) convened meetings of the presidents of 
rural communities and sou-préfets in his or her département, at which the aims and activities of the project were 
explained using an information sheet.
Each medical district developed its own communication plan and money was given to be used for raising 
community awareness about the intervention. As the importance of informing caregivers of the timing of SMC 
days before every round was a lesson learnt from pilot study, activities were organised before the first round in 
September and again before each of the subsequent courses. In Fatick, Niakhar and Mbour, information about the 
intervention was broadcast on local radio stations, and phone-in programmes were organised in which project 
staff answered questions. In Bambey, griots (village criers) went to selected villages accompanied by the district 
public health officer. In all districts, village meetings were organised, heads of neighbouring villages were invited, 
and question and answer sessions were led by the district public health officer, the district medical officer or 
members of the research team. As in the pilot study, the importance of providing opportunities for questions to 
be asked was a key finding. These activities were facilitated by the Préfets and sous-Préfets and the Présidents des 
Communautés Rurale who provided some of the transport and logistics for these activities. To improve awareness 
about the intervention and in response to qualitative findings in the pilot, CHWs were given T-shirts and caps 
bearing project insignia, which they wore during the SMC rounds.
Eligibility: From 2008, the lower age limit was raised from 2 months to 3 months because of the low risk of 
malaria in very young infants. From 2009, in response to the changing malaria epidemiology which was then 
apparent, the upper age limit was extended from 59 months to 119 months.
Adapting the delivery approach to include older children: A further consultation was held between district 
medical officers, health post nurses, community health workers and researchers to discuss implications of extend-
ing the programme to include older, school-age children. Delivery through schools was considered, this would 
be relevant only for the last month of delivery as other months are outside school terms, but was not pursued as it 
would exclude children not enrolled and those not attending school when SMC was delivered. Delivery would be 
scheduled at times when older children were likely to be at home, on Fridays, evenings and weekends.
Drug dosage and formulation: With the expanded age range from 2009, a third age category was created for 
dosing. Children aged 72 to 119 months, should receive 1.5 tablets of AQ and SP on day 1 and 1.5 AQ tablets on 
days 2 and 3. Also from 2009, the composition of SP was changed from sulfalene to sulphadoxine because of a 
change in supplier. In October and November 2010, a different formulation of SP and AQ was used which was not 
only breakable, but also dispersible and sweetened, to facilitate administration (Table S1).
Drug administration: In 2008, the CHWs were provided with cups and spoons with which to administer the 
tablets as they had been in the pilot study, however, this raised concerns amongst carers about hygiene, and also 
seemed an unnecessary expense for the programme. From 2009, CHWs therefore used the household’s own cups 
and spoons, and provided the tablets to older children to be swallowed whole under observation.
Training head nurses and community health workers: In 2008, all 9 head nurses whose health posts were 
randomized to implement SMC gathered in the IRD research center of Mbour for a 2-day training. BC and EHB 
led the training, while the four head nurses who implemented the pilot were also present and shared their expe-
riences. In 2009 and 2010, head nurses who implemented SMC in 2008 trained those who were implementing 
SMC for the first time.
In all three years, each implementing health post held a one-day training session on the day preceding the 
commencement of the September round of SMC delivery.
Record keeping: Registers were used to record monthly treatment, and tally sheets to record number of treat-
ment doses. With the implementation of a demographic surveillance system (DSS, described below) from 2008, 
families were issued with SMC record cards, one for each caregiver, on which SMC treatments of children in their 
care were recorded.
Logistics and timing: Administration was planned to begin on the same date in all health posts each month 
and year. The 5-day period at the middle of each month was chosen taking into account public holidays, and other 
health activities of district staff. Community sensitization and local mobilisation were organised by the district 
communication officer. In September 2010, each health post was provided with a printed register for each village 
in their catchment area, listing eligible children.
Drug procurement and management: In 2008, drugs for SMC (Dualkin, sulfalene-pyrimethamine and amo-
diaquine) were donated by Pfizer, Dakar; sulfalene is chemically very similar to sulfadoxine. Drugs were pur-
chased in 2009 from planet Pharma, Paris representing Chongqing Qinyang Pharmaceutical Co Ltd and in 2010 
from Kinapharm (AQ 153 mg and SP 500 mg) and National pharmacy of Senegal (SP 500 mg).
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A sample of SP and AQ tablets was tested in Dakar (Laboratoire des pharmacies et des médicaments) and 
London (London School of Hygiene & Tropical Medicine) and passed standard criteria for drug content, uni-
formity of content, dissolution and impurities.
Drugs were stored in the research facility in Mbour under supervision of the field research coordinator. The 
quantity of drugs needed for each district was calculated based on the population of children in each age-based 
dosing group plus a margin of 20%. Populaton estimates came from a census done in 2008 updated through 
demographic surveillance rounds. District staff or, in some cases, the health post nurses transported the drugs to 
the health posts at least 3 days before drug delivery was due to commence each month. The day before drug deliv-
ery each month, CHWs at each health post placed courses of tablets appropriate for each age group into plastic 
bags. Remaining drugs from each round were kept in health posts after the September and October campaigns 
and the additional tablets required given before the following month based on number of children seen during 
the previous month. At the end of the November rounds, all remaining drugs were sent back and stored in a con-
trolled temperature room at the research health facility in Mbour.
Supervision and monitoring: At end of each day, the CHWs reported to the head nurse the number of chil-
dren seen and drugs remaining, and checked the register for any children who had been missed. The nurse then 
tallied the total number of AQ and SP tablets administered, counted the number of tablets remaining, calculated 
wastage, and, if less than the predicted number of tablets had been used, sought reasons for the discrepancy (e.g. 
refusals, errors in listings, migration of families). The nurse then reported this information to the district medical 
officer each day by mobile telephone and issued CHWs with drugs for the next day.
In 2008, the 9 implementing health posts continued to receive daily supervisory visits during the delivery days 
from either district or research staff. In addition, project DSS (Demographic Surveillance System) interviewers 
visited each nurse and each CHW team in their DSS circuit once per SMC round to check the team had forms and 
registers and used them correctly, had enough drugs, sugar, and other supplies, and were correctly dosing by age. 
In 2009 and particularly in 2010, however, as the number of health posts increased, the research team scaled back 
their support such that the DHMTs supervised largely unaided.
Pharmacovigilance: A series of steps were taken to strengthen the national PV system in the study districts8.
Costing: A detailed costing study was undertaken in 2010, reported elsewhere9.
Data collection. Data sources comprised a demographic surveillance system (DSS), administrative data, a series 
of cross-sectional household surveys, and a survey of CHWs. Data were recorded on paper forms and scanned 
into databases using the Teleform system.
Demographic Surveillance System: A census of the study area was carried out in March-May 2008. After 
data entry and cleaning, all households were revisited in August to give each mother or caregiver a card bearing 
an identification number for the household, for the mother/caregiver, and for each child in her care, with space to 
record information on the administration of SMC, Vitamin A, and mebendazole. Health facilities were provided 
with blank DSS cards to issue to first-time mothers at their first contact with health staff after delivery, and annual 
rounds of household visits were conducted to record changes in household occupancy.
Administrative data: Tools to document the drug administration process (quantity of drug given, date and 
age group) were developed and given to each team of CHWs. Register were printed out from the demographic 
surveillance system data base with information to identify each child (mother’s name, name of head of house-
hold, household number, village name and number - with columns to document presence, absence, refusal of 
treatment, and whether the child vomitted). The registers were printed once per year with columns on each page 
to collect information for each child each month. Tallies were made from registers to determine the number of 
refusals, and absent and sick children each round each year.
Cross-sectional household surveys: Surveys were conducted at the end of the malaria transmission season 
in December 2008, 2009, and 2010 to determine coverage of SMC and reasons for missed doses, adherence to 
daily doses in the most recent SMC treatment, to record bed net use by children after inspecting the place where 
the child slept, to measure the prevalence of parasitaemia and anaemia, and to ask about any adverse events 
related to SMC. In 2008, 5 villages in the catchment area of each of the 54 health posts implementing SMC were 
selected with probability proportional to size. In each selected village, households were selected by simple random 
sampling from the Demographic Surveillance System (DSS) database to yield at least 20 children in each village, 
giving a minimum sample of 100 children per health post, or 5,400 in total. In 2009, the sampling strategy was 
modified somewhat: households were selected in each health post’s catchment area by simple random sampling 
from the DSS database to give a sample of at least 130 children per health post, resulting in an actual total sample 
size of 6,827 children. In 2010, to improve the power for analysing parasitaemia prevalence, the sampling strategy 
was again modified to over-sample the 9 remaining control health posts and those with higher malaria incidence 
by weighting each by a factor of 2 before randomly selecting 40 health posts with probability proportional to size. 
In each selected health post, households were selected by simple random sampling to yield about 25 children in 
each health post and 1000 children in total.
The DSS database was used to determine the number of households to sample in each village or health post to 
generate the required sample size. A list of all eligible children in the selected households was prepared from the 
DSS database, but interviewers were instructed to recruit all children within the appropriate age range normally 
resident in the household, regardless of whether they were in the DSS listing or had received SMC. “Normally 
resident” was defined as children who had been resident for at least 6 months or, if resident for less than 6 months, 
planned to remain in the area for the next 6 months. In December 2008, all normally resident children aged 
(when surveyed) 6–63 months in the sampled households were included in the survey, and in December 2009 
and 2010, all normally resident children aged (when surveyed) 6 to 123 months were included. While children 
who reached the age of 3 months after the September SMC round, but before the October or November rounds 
were eligible to receive SMC in the later months, they were not included in the December survey. In all surveys, 
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the sampling fraction varied between health posts in order to yield an approximately constant number of children 
per health post. If the target number of children was not reached after all the selected households had been visited 
and call-backs completed, an additional listing of households, selected by simple random sampling from the same 
health post, was used. Sampling continued until the target sample size was reached.
The survey was conducted over 14 days each year. Interviewers alternated between health posts that had 
received SMC and those that had not to avoid systematic bias in the timing of the interviews. One call-back visit 
was arranged if the mother or a child was absent.
The mother (or other caregiver) of each child was asked about her demographic characteristics, education, 
sources of income, household and personal assets, type of house and availability of electricity, telephone and water 
supply. For each child, the duration of residence in the village was recorded, and the place where the child slept 
the previous night was inspected to record the type and condition of the net. In areas where SMC had been deliv-
ered, the number of SMC courses received was recorded from the DSS card if available or from mother’s recall. If 
scheduled SMC doses were not received, the mother was asked the reasons.
Community health worker survey: At the end of 2010, a survey was conducted of a sample of 47 CHWs, 
from all four districts, addressing their experience of SMC delivery. They were asked what questions were most 
commonly raised by caregivers; what they did if the child was febrile; whether they enquired, before administer-
ing SMC, if they child had had adverse reactions to SMC drugs previously or had known allergy to SMC drugs; 
whether cups, spoons, water and sugar were provided by the household or the health post; the steps taken to treat 
school-age children during term time; how they determined the child’s age group for dosing (under 2 yrs, 2–5 
yrs, 6 yrs and over) when the child was not in the DSS listing; whether they had knowingly treated children older 
than 10 years; what happened if the mother said there was a child that should be treated but the child was not at 
home when the CHW came; whether they consistently checked if the child had received other medicines in the 
last month, specifically SP or AQ or bactrim, and whether or not they administered SMC in such cases; and if 
the child was currently on a course of antimalarial treatment, whether they administered SMC. It was explained 
that the aim of the survey was to determine what was done in practice and there were no right or wrong answers.
Data management and analysis. Coverage levels: Administrative data on the number of courses administered 
was tallied from health centre registers and aggregated by district. Reports from health posts and delivery tools 
developed to document day to day activity of drug delivery teams were collected and compared with registers to 
check for consistency.
Survey questionnaires were checked for completeness by the district supervisor before being batched and 
sent to Dakar for scanning using the Teleform system and export to Access databases. The proportion of eligible 
children receiving 0, 1, 2, and 3 courses of SMC and 95% confidence intervals were estimated from the survey 
data using a ratio estimator, with each observation weighted by the inverse of the sampling fraction for the health 
post using Stata version 11 (Statacorp, College Station, Texas). For 2009 and 2010 data, coverage levels were also 
estimated by age group to compare annual coverage for children aged 3 to 59 months with coverage of those aged 
60 to 119 months in September of each year; p-values were calculated using the designed-based F test.
Equity: Equity of coverage was conceptualized as children having the same probability of receiving SMC 
regardless of their age (within the target age range), gender, the household’s socio-economic status (SES), or their 
mother’s education type or level. Analyses were based on the cross-sectional household surveys. Each child’s 
SES quintile was assessed using principal components analysis of his or her mother’s assets (ownership of cattle, 
sheep, goats, horses, donkeys, radio, television, video cassette recorder, watch, telephone, metal or wooden bed, 
bicycle, cart, motorbike, car), household construction (roof material, floor material), and household amenities 
(running water, electricity, fixed phone line, flush toilet, pit latrine, solar power, cooking fuel). The proportion of 
children who had received all three intended courses of SMC and the proportion who had slept under a bed net (a 
long-lasting insecticide-treated bed net (LLIN), any treated or impregnated bed net, or any net) the previous night 
were then disaggregated by SES quintile. Logistic regression was used to calculate the change in odds of coverage 
for a one quintile increase in SES. Test for trend for SES was done using logistic regression model fitting SES as a 
linear effect and accounting for survey design using STATA survey commands. Coverage of SMC was also com-
pared across the level and type (none, Koranic, or French) of the mother’s education. Differences between groups 
were compared using design-based p-values.
Ethics. The trial protocol was approved by Senegal’s Conseil National pour la Recherche en Santé and the ethics 
committee of the London School of Hygiene & Tropical Medicine. The trial is registered at www.clinicaltrials.gov, 
number NCT 00712374.
During each round of SMC, CHWs explained the aims of the project, the purpose and potential side effects 
of the study drugs, using a standard script translated into the appropriate local language (Wolof or Serer), sought 
verbal consent from the mother or caregiver of each child, and recorded consent or refusal in a register.
Consent was sought separately for participation in cross sectional surveys. After publicizing the survey in 
the community through meetings with CHWs, the village head, and public meetings, DSS interviewers visited 
selected households. They explained the aims and procedures of the survey, using a standard information sheet, 
and sought written consent from the mother or caregiver of each eligible child.
Large-scale implementation results. Courses of SMC delivered. In the three years of the main imple-
mentation study, children aged at least 3 months and under 10 years received more than 780,000 courses of 
SMC. (Table 3) The number of courses received reflects instances in which a CHW successfully administered or 
observed a child take the first day’s dose of AQ and SP and provided AQ tablets for administration on the two fol-
lowing days. In a relatively small number of additional instances, a child was reached by a CHW, but the parents 
or child refused (7,660, 0.97% of contacts), the child vomited or spat out the first dose (892, 0.11%), or the child 
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was unwell and therefore ineligible to receive SMC, in which case the child was referred to a health facility (314, 
0.04%). In addition, 7% of targeted children were absent in 2008 and this rose to 13% in 2009, but then dropped 
to just 3% in 2010 (Table 3).
Quality of delivery. At each health post, SMC delivery took between 2 and 6 days each month and involved 
between 4 and 68 CHWs. Each pair of CHWs administered SMC to approximately 54 children per day in 2008 
(Table 1). As virtually doubling the age range only increased the number of households to visit by 13%, the aver-
age number of children receiving SMC from each pair of CHWs increased to 78 per day in 2009 and 88 per day 
in 2010.
The system of daily supervisory visits at every health post on every administration day in 2008 picked up a 
number of errors promptly. For example, in September 2008, an excess of SP tablets had been used in 3 health 
posts, and the supervisor discovered that this was because SP as well as AQ had been left with the mother for 
administration at home on days 2 and 3. In response, CHWs were sent back the same evening to collect the SP, 
all nurses were telephoned to remind them of procedures, and training in future years further emphasized the 
dosage, such that the problem did not recur.
Staff turnover was low both amongst head nurses and CHWs. Only 5 of 46 nurses left their health post during 
the three years, and three of these 5 remained in the study area.
In the resource use and activity survey conducted in 2010, nearly all CHWs declared that this was their first 
time (from 2008) delivering SMC. Questions most commonly asked by caregivers were about the purpose of 
SMC; why adults were not included; why these drugs (SP, AQ) were used; why children can become unwell after 
taking the drugs and questions related to side effects; and whether SMC would eliminate malaria. 37/47 (79%) of 
CHWs said they consistently referred febrile children to the health post and did not give SMC treatment, but 4 
(9%) had treated febrile children and 7 (15%) had with-held treatment without referring. Checking for previous 
side effects or known allergies to SMC drugs was not routinely done. It was stated by several CHWs that this 
was because they felt that if there had been side effects, mothers would volunteer this information without being 
asked. 38 (81%) said that the sugar they used in the previous SMC was provided by the project and 9 (19%) said 
they used sugar provided by the household. When asked about steps they had taken to treat school-age children, 
36 (77%) said they had returned to the household in the afternoon, 4 (9%) said they had made appointments 
for the following day, 7 (15%) said treatments had been given at school supervised by the school director, and 4 
(9%) said they had left drugs for this child with parents. For determining the dose to use, vaccination cards were 
checked but if these were not available, the age was estimated by comparison with other children in the com-
pound. One CHW (2%) had treated children above 10 years of age. To treat children who were not present at the 
time of the visit, 27 (57%) mentioned making an appointment to return the following day, 13 (28%) mentioned 
leaving the treatment with the mother, and 7 (15%) mentioned going to find the child nearby. None of the CHWs 
surveyed said that they checked if the child had received SP, AQ or Bactrim in the previous month. Most (89%) 
said they would not administer SMC if the child was currently on a course of antimalarial treatment, but 5 (11%) 
said they would.
Levels of coverage. According to administrative data and DSS population estimates, average monthly coverage 
increased from 76% in 2008, to 83% in 2009, and up to 87% in 2010 (Table 4). Coverage varied from a low of 65% 
of children in the target age range (3 to 59 months) receiving SMC in Mbour district in November 2008 to a high 
of 92% of children in the target age range (3 to 119 months) receiving SMC in Bambey district in November 2010.
Cross-sectional surveys indicated that in 2008, 92% (95% Confidence Interval: 89%, 95.5%) of children in 
the target age range (3 to 59 months) received all three monthly courses of SMC (Table 5). In 2009, when both 
the target area and age range increased, estimated coverage decreased to 84% (82%, 87%) of targeted children 
receiving all three courses of SMC. In 2010, estimated coverage with all three monthly courses of SMC increased 
Month
2008
(children 3–59 months, 3 health posts)
2009
(children 3–119 months, 27 health posts)
2010
(children 3–119 months, 46 health posts)
TOTALSep Oct Nov Total Sep Oct Nov Total Sep Oct Nov Total
Received 
SMC
16,218 
(90.31%)
15,756 
(91.77%)
14,764 
(90.62%)
46,738 
(90.89%)
86,949 
(85.32%)
86,514 
(84.88%)
88,553 
(85.04%)
262,016 
(85.08%)
154,014 
(96.57%)
157,602 
(96.63%)
159,667 
(96.63%)
471,283 
(96.61%)
780,037 
(92.07%)
Absent 1,544 (8.60%)
1,114 
(6.49%)
1,079 
(6.62%)
3,737 
(7.27%)
14,147 
(13.88%)
13,956 
(13.69%)
13,079 
(12.56%)
41,182 
(13.37%)
4,600 
(2.88%)
4,411 
(2.70%)
4,385 
(2.65%)
13,396 
(2.75%)
58,315 
(6.88%)
Refused 45 (0.25%)
145 
(0.84%)
292 
(1.79%)
482 
(0.94%)
649 
(0.64%)
1,317 
(1.29%)
2,429 
(2.33%)
4,395 
(1.43%)
655 
(0.41%)
1,007 
(0.62%)
1,121 
(0.68%)
2,783 
(0.57%)
7,660 
(0.90%)
Vomited 
or spat 
out
142 
(0.79%)
146 
(0.85%)
145 
(0.89%)
433 
(0.84%)
68 
(0.07%)
55 
(0.05%)
35 
(0.03%)
158 
(0.05%)
177 
(0.11%)
72 
(0.04%)
52 
(0.03%)
301 
(0.06%)
892 
(0.11%)
Unwell 10 (0.06%)
8  
(0.05%)
13 
(0.08%)
31 
(0.06%)
94 
(0.09%)
82 
(0.08%)
38 
(0.04%)
214 
(0.07%)
41 
(0.03%)
13 
(0.01%)
15 
(0.01%)
69 
(0.01%)
314 
(0.04%)
TOTAL 17,959 (100.00%)
17,169 
(100.00%)
16,293 
(100.00%)
51,421 
(100.00%)
101,907 
(100.00%)
101,924 
(100.00%)
104,134 
(100.00%)
307,965 
(100.00%)
159,487 
(100.00%)
163,105 
(100.00%)
165,240 
(100.00%)
487,832 
(100.00%)
847,218 
(100.00%)
Table 3. Effective coverage: Receipt of SMC and reasons for not receiving. Findings are presented from 
administrative data.
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to 93% (91%, 96%) of children in the targeted age range and areas, the highest level achieved in any of the 5 years 
of the study. Fewer than 5% of children received one or two courses of SMC in any given year. The proportion 
of children captured in the end-of-season surveys who were reported not to have received any courses of SMC 
increased from 3.5% (2%, 5%) in 2008 up to 11% (9%, 13%) in 2009, and then decreased to 6% (4%, 8.5%) in 2010. 
Estimated coverage in each month is shown in Table S4.
For all three years, the cross-sectional survey data provided higher coverage estimates than the combination 
of our administrative data and DSS, which likely reflects differences in denominators. The DSS estimated the 
total population normally resident in the study area, whereas the cross-sectional surveys excluded people who 
were temporarily absent at the time of the surveys. The DSS estimates are therefore likely to have overestimated 
the target populations and underestimated coverage, because some families had temporarily migrated, and were 
therefore not present to receive SMC and potentially not even exposed to malaria.
The surveys also indicated a notable dip in coverage in 2009, whereas the administrative data indicated contin-
uous increases in average yearly coverage. This discrepancy likely relates to the relatively high proportion of chil-
dren who were absent during SMC delivery in 2009 (15%) as compared with 2008 (8%) or 2009 (3%) (Table 3); 
District
Year 2008 2009 2010
Month Sep Oct Nov Sep Oct Nov Sep Oct Nov
Number of health 
posts implementing 9 27 46
Target age range 3–59 months 3–119 months 3–119 months
Bambey Courses of SMC administered 4,677 4,250 4,104 38,673 38,583 41,102 74,047 76,018 77,292
Target population 5,092 5,092 5,092 46,208 46,208 46,208 83,756 83,756 83,756
Coverage 92% 83% 81% 84% 83% 89% 88% 91% 92%
Fatick and 
Niakhar
Courses of SMC 
administered 5,189 4,903 4,912 27,253 26,908 26,182 45,565 46,274 47,375
Target population 6,482 6,482 6,482 32,659 32,659 32,659 53,863 53,863 53,863
Coverage 80% 76% 76% 83% 82% 80% 85% 86% 88%
Mbour Courses of SMC administered 6,352 6,603 5,748 21,023 21,023 21,269 34,402 35,310 35,000
Target population 8,836 8,836 8,836 26,507 26,507 26,507 43,441 43,441 43,441
Coverage 72% 75% 65% 79% 79% 80% 79% 81% 81%
Total Courses of SMC administered 16,218 15,756 14,764 86,949 86,514 88,553 154,014 157,602 159,667
Target population 20,410 20,410 20,410 105,374 105,374 105,374 181,060 181,060 181,060
Coverage 79% 77% 72% 83% 82% 84% 85% 87% 88%
Table 4. Effective coverage by district. Coverage estimates are based on administrative data and DSS population 
estimates.
Age range
Year 2008 (N = 1,019) 2009 (N = 3,397) 2010 (N = 882)
Number of 
courses received
Point 
estimate 95% CI
Point 
estimate 95% CI
Point 
estimate 95% CI
3–59 months 0 3.5 1.9, 5.1 12.9 10.4, 15.5 8.8 4.9, 12.8
1 0.9 0.2, 1.5 2.2 1.4, 3.1 0.4 −0.2, 1
2 3.3 0.8, 5.8 3.3 2.0, 4.6 0.4 −0.1, 0.9
3 92.3 89.1, 95.5 81.6 78.4, 84.8 90.4 86.4, 94.3
60–119 months 0 NA NA 9.4 7.3, 11.4 3 1.3, 4.6
1 NA NA 0.9 0.3, 1.4 0 0, 0
2 NA NA 2.7 1.5, 4.0 0.7 −0.1, 1.6
3 NA NA 87 84.5, 89.6 96.3 94.4, 98.2
Overall coverage 0 3.5 1.9, 5.1 11.1 9.2, 13.0 6.1 3.7, 8.5
1 0.9 0.2, 1.5 1.5 1.0, 2.0 0.2 −0.1, 0.5
2 3.3 0.8, 5.8 3 1.8, 4.1 0.6 0.1, 1.0
3 92.3 89.1, 95.5 84.4 81.9, 87.0 93.1 90.6, 95.6
Table 5. Effective coverage by age group. Coverage estimates are based on end-of-season cross-sectional survey 
data. In 2008 SMC was only given to children under 5 years. Children missing information on the number of 
SMC courses received are assumed to have received no courses. Number of courses received was not missing for 
any children in 2008 or 2010. Number of courses was missing for 5 children (0.15%) in 2009. *Age was missing 
for two children in 2009 and one child in 2010, and so these three children are reflected in overall coverage, but 
not the age-specific coverage estimates. Design-based test of homogeneity of proportions by age group: 2009, 
p < 0.001; 2010, p = 0.0018.
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perhaps because of less effective communication, families may have been temporarily away from home on the 
delivery days in 2009, but nonetheless captured in end-of-season survey that year.
In 2009, 9.6% of caregivers reported difficulty administering the unsupervised doses; this percentage was 
slightly lower for children 5–9 years (7.4%) than for under-5’s (12%). The most common problems (76% of those 
reporting difficulties) were refusal or rejection by the child. Other reasons included the caregiver being away, and 
the child being unwell. Only 2% said they had forgotten to give the two doses or had lost the tablets.
Equity of coverage. In 2009, coverage was somewhat higher amongst children aged 5 to 9 years (87%, 95% con-
fidence interval 84.5%, 90%) than amongst children under 5 (82%, 95%CI 78%, 85%, p < 0.001). Although cov-
erage increased substantially in both age groups the following year, coverage remained higher in older children 
(p = 0.002, Table 5).
Figure 3 shows that there was no evidence of a linear trend in the probability of receiving all 3 courses of SMC 
across SES quintiles in either 2008 (p = 0.63) or in 2009 (p = 0.36), the two years for which SES data was collected 
(Supplementary Table S2). In 2008, coverage of all three intended courses of SMC in the poorest SES quintile was 
estimated at 94.5%, which was higher than all but the highest SES quintile, which achieved 94.9% coverage. In 
2009, all coverage levels dropped across all quintiles, but the 85.3% coverage achieved in the poorest quintile was 
only slightly lower than the 87.5% coverage in the highest quintile.
Coverage of SMC was also equitable with respect to the education of the child’s mother. Figure 4 illustrates that 
there was no evidence in 2008 (p = 0.55), 2009 (p = 0.77), or 2010 (p = 0.33) of differences in coverage according 
to whether the mother had no education, only a Koranic education, or any French education (Supplementary 
Table S3). In all three years, coverage levels were very similar between groups, and in both 2008 and 2010, chil-
dren whose mothers had no education achieved the highest levels of SMC coverage.
This equitable and very high coverage of SMC contrasts sharply with the inequitable and lower rates of use 
of bed nets shown in Fig. 3. In both years analysed, there was very strong evidence of a regressive trend in those 
children who had slept under a long-lasting insecticide-treated net (LLIN), any treated net, or any net in the night 
preceding the survey (Supplementary Table S2). In 2008, use of an LLIN in the night preceding the survey varied 
from 54% in the poorest SES quintile to 69% in the highest SES quintile, reflecting an 18% (8% to 29%) increase 
in the odds of LLIN use for each level increase in SES quintile. In 2009, the inequity in bed net usage became even 
starker as only 39% of children in the poorest quintile had slept under an LLIN the preceding night compared 
with 75% of children in the highest SES quintile. The odds ratio for the increase in coverage corresponding to 
an increase of one level in socioeconomic ranking, was 1.0 (95% CI 0.88, 1.2) for receiving 3 SMC treatments in 
2008, and 1.1 (0.95, 1.2) in 2009, compared with odds ratios of 1.2 (1.1, 1.3) and 1.3 (1.2, 1.5) for sleeping under 
an LLIN in 2008 and 2009 respectively.
Discussion
This study demonstrated that SMC could be effectively delivered on a large scale through routine health services 
using a door-to-door approach, achieving high and equitable coverage, with good adherence to supervised and 
unsupervised daily treatment doses. Over 5 years, implementation was gradually scaled up from pilot delivery of 
SMC to more than 5,000 children in 3 health posts in 2006 to large-scale delivery to more than 150,000 children 
in the catchment areas of 46 health posts in 2010. The coverage of SMC achieved was consistently higher than 
and more equitable than that of bednet use, indicating that SMC reached children who were not protected by 
bed nets, and the strategy successfully reached older school-age children. These findings strengthen the case for 
implementing SMC door-to-door, and for including older children.
Coverage was defined in terms of the number of treatments received and therefore did not capture SMC 
contacts where the child was referred to the clinic and did not receive SMC treatment at the clinic. An alternative 
definition of coverage, counting all contacts where the guidelines were followed, could also be defined. SMC 
record cards would need to be modified to capture such contacts.
Figure 3. Equity of receipt of SMC and use of bed nets by socio-economic status in 2008 and 2009 (Under-5 s in 
2006 and 2008, under-10 s in 2009. LLIN: Long-lasting insecticide-treated bednet).
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Findings from this study contributed to the policy recommendation for SMC1 and the field guide for SMC10. 
The WHO guide should be consulted for the currently recommended approach to SMC administration. Separate 
tablets for infants and children are now available in blister packs, avoiding the need to break tablets, in dispersible 
formulations.
It had been questioned whether SMC could be delivered on a large scale in the absence of an established 
delivery route for reaching older children once a month. The demonstration of feasibility and acceptability on a 
large scale was therefore a necessary step before a policy recommendation1 could be made. The size of the study 
(which was originally motivated by power calculations to measure the effect on mortality), permitted piloting of 
delivery on a large scale. The study was also able to demonstrate that good compliance with monthly treatments 
and adherence to daily doses could be achieved through a door-to-door approach with supervision of the first 
dose and the remaining doses being administered by the caregiver.
Engagement between researchers and health staff at all levels during the planning phase was a key step in 
choosing a suitable delivery approach and in planning the evaluation. The study also benefitted from international 
consultations between researchers involved in SMC and policy makers, which were organised independently of 
this study, a meeting in Dakar in 2008 and a meeting with WHO GMP in early 2010 which led to a refinement of 
the delivery approach and additional data collection to allow more detailed assessment of safety and costs.
In 2011, the Technical Expert Group on Chemoprevention met to review evidence on SMC11. One recommen-
dation of this group was that SMC should be prioritised in areas where the incidence of malaria was at last 0.1 
episodes per child during the main transmission period as it was expected that the intervention would be highly 
cost effective in such circumstances. The study area fell outside this recommendation, but since 2013, Senegal’s 
National Malaria Control Programme in Senegal has implemented SMC in the southern regions of the country, 
where transmission is more intense. In 2017, twelve countries in the Sahel and sub-Sahel, including Senegal, have 
SMC programmes. In Senegal, the decision was taken to include children up to 10 years of age in the national 
SMC programme. Our study has shown that school-age children can be effectively reached and the time for deliv-
ery was not greatly increased by including these children.
A door-to-door approach was employed in this study. Experience with different modes of delivery is being 
gained12,13 and evaluations are being undertaken through the ACCESS-SMC project14. Delivery through fixed 
points has been less effective than delivery door to door. In a pilot project in Mali13, SMC was delivered at a central 
point in each village, or at the health centre, the first daily dose administered by health workers and the remaining 
doses left with the caregiver. Coverage was lower than in our study (average coverage of first doses was 77% over 
4 cycles, and 54% received treatment at all 4 cycles).
Door-to-door approaches are also used for polio campaigns, biannual health days for Vitamin A and deworm-
ing, and LLIN campaigns and azithromycin campaigns for trachoma, but few evaluations of the delivery approach 
have been published. Combining SMC with Vitamin A delivery was piloted in this study in three health posts. 
The complication of different dosing by age necessitated the presence of an additional person in each CHW 
delivery team. A larger evaluation had been planned but the supply chain and finance for Vitamin A is coordi-
nated independently of the malaria control programme and synchronisation of SMC and Vitamin A delivery was 
problematic in practice. Combining SMC with community case management has been shown to offer substantial 
advantages15. Combining SMC with other strategies, including nutritional screening, requires further evaluation.
Our study offers several practical insights for implementation research. While we designated the first two 
years as “the pilot study”, the delivery strategy continued to be adapted, with changes to the delivery strategy in all 
three years of the “large-scale implementation”. Modifications were made to improve the programme, to respond 
to problems that arose, for example with suppliers, and to move towards a delivery model in which researchers 
Figure 4. Equity of SMC coverage by mother’s education in 2008, 2009, and 2010 The figure presents the 
proportion of children targeted to receive SMC who received 0, 1, 2, or 3 of the 3 intended courses of treatment 
each year, disaggregated by whether the child’s mother had no education, some Koranic education only, or some 
French or French and Koranic education.
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played little or no role. In our study, SMC courses were recorded in a register and on the mother’s card. Accurate 
recording of courses received is essential if impact is to be monitored, using, for example, case control studies to 
measure efficacy of the intervention or rebound effects, and for adverse event monitoring. Publicity campaigns 
and other sensitization activities played an important role in ensuring good uptake, and weaknesses in this area 
likely explain the dip in coverage and the high rate of absences in 2009, which was remedied in 2010. We have 
identified a number of practical lessons for large-scale implementation, including the importance of engagement 
between researchers and health staff at all levels during planning, and the value of piloting and gradual scale-up. 
High coverage was achieved in older, school-aged children, by informing community leaders and school teachers 
about dates of SMC administration, and by delivering the treatment on Friday afternoons and weekends.
This was the first study to evaluate implementation effectiveness of SMC under operational conditions, and to 
assess the feasibility of reaching older children. Robust methods were used for estimation of coverage and equity. 
Age-specific tablet strengths designed and packaged for SMC, which are now available, were not available at the 
time the study was conducted. These new products may reduce administration errors and permit more precise 
dosing as they avoid the need to break tablets, and may promote adherence. However, highly effective delivery 
was possible with the single-strength loose tablets used in the study. Involvement of researchers may have con-
tributed to implementation effectiveness but this involvement was limited and reduced over the curse of the 
implementation. Quantification of drug requirements benefited from the existence of the DSS system and listings 
of children may have helped correctly to identify eligible children and their dose.
Conclusion
Seasonal malaria chemoprevention can be delivered on a large scale through routine health services and achieve 
high and equitable coverage both amongst children under 5 and amongst children aged 5 to 9 years. The existence 
of a well-functioning CHW network and wider primary health care system, close collaboration with local health 
workers from the start, and gradual scale-up and adaptation of intervention methods all contributed to the suc-
cess of implementation. Our experience offers several practical lessons both for those implementing SMC and 
those considering other campaigns delivered through community health workers. Delivering SMC to school-age 
children is feasible and the results of this study should encourage countries with SMC programmes to consider 
including older children in SMC programmes.
Data availability statement. Surveillance System data, and individual-level survey data, are available 
at http://dx.doi.org/10.17037/DATA.117. Requests for access will be reviewed by a Data Access Committee to 
ensure use of the data protects participant privacy according to the terms of participant consent and ethics com-
mittee approval.
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